BioCurate
@BioCurate
Followers
2K
Following
3K
Media
468
Statuses
2K
A joint venture between @monashuni & @unimelb to catalyse the translation of #biomedical & #biopharma research toward commercialisation. #Discoveries2Drugs
Parkville, Melbourne
Joined June 2017
Monash University researchers are developing a novel treatment for pulmonary arterial hypertension (PAH), with crucial support from @BioCurate's Proof of Concept Fund. The team aims to create a disease-modifying therapy for this progressive, incurable condition affecting mainly
1
1
7
And the exciting part 😍 Oral presentation winners: @KhabibHamizan #1 student oral p @ChloeLi595 #2 student oral p @BhavanaNayer #1 postdoc oral p Kristy Swiderski #2 postdoc oral p @DaleFTaylor people's choice
2
3
8
Final program for the #I2T2024 symposium includes: 🌟 Invited speakers from across the Melbourne biotech sector 🏆 Updates from past MTx pitch competition winners 🎙️Expert panel on research commercialisation – sponsored by @BioCurate
https://t.co/J9G5hxNSpc
eventbrite.com.au
A showcase of the current commercial & translational research occurring across the Parkville Biomedical Precinct.
0
1
3
🌟 A huge thank you to everyone who joined us at @AusBiotech 2024! We celebrated collaboration and innovation—key to @BioCurate's mission of translating exceptional research into impactful therapies. Key highlights include engaging discussions and networking with industry
0
0
1
Just wrapped up an insightful panel on 'Considerations when investing in early-stage university spin-outs' at #AusBio2024! 🎉 Dr Kathy Nielsen @BioCurate, shared expertise alongside representatives from Brandon Capital, @MonashUni, @UniseedFund and SYNthesis BioVentures. Exciting
0
0
1
🚨 Attention #AusBio2024 attendees! 🚨 Don't miss out on the "Considerations when investing in early-stage university spin-outs" panel today at 2:20 PM - 3:05 PM! 🕑 Our very own Dr Kathy Nielsen, CEO at BioCurate, will be sharing her expertise alongside: Dr Michael Bettess
0
0
1
#AusBio2024 is well underway! Don’t forget to visit BioCurate at the @VicGovAu Pavilion booth #4. We look forward to forming new connections with the sector. Stay tuned as we’ll be tweeting throughout the conference. @AusBiotech
0
0
2
#AusBio2024 has officially kicked off today! Don't miss the opportunity to visit us at the @VicGov booth #4. Our team is also available to connect through the AusPartnering program. Attending: Dr Kathy Nielsen, CEO Dr Francis Kirby, Partnerships and Strategy Manager, Dr
0
0
3
We're grateful to the dedicated team working on this partnership, including: L-R: Dr Belinda Huff, Dr Andrew Harvey, Dr Matthew McLachlan, Dr Malika Kumarasiri, Dr Eric Hayes, Dr Nick Matovic, Dr Brian Dymock, Dr Julia Beveridge @BioCurate #UniQuest #QEDDI
BioCurate is excited to announce a new partnership with UniQuest’s #QEDDI, with the aim to develop a new effective treatment for neuropathic pain with potential to become a safe alternative to opioids. Read more via: https://t.co/nteEoAsdfa
#QEDDI #UniQuest #drugdiscovery
0
0
0
“There is so much need for new treatments and pooling resources and expertise through early-stage partnerships such as this one between BioCurate and #QEDDI is vital to success.” - Dr Kathy Nielsen, CEO of @BioCurate
#UniQuest #drugdiscovery #smallmolecules,
0
0
1
BioCurate is excited to announce a new partnership with UniQuest’s #QEDDI, with the aim to develop a new effective treatment for neuropathic pain with potential to become a safe alternative to opioids. Read more via: https://t.co/nteEoAsdfa
#QEDDI #UniQuest #drugdiscovery
1
0
1
Connecting capital with health innovation at #AusBioInvest2024! BioCurate CEO Dr Kathy Nielsen joins other industry leaders today for ground-breaking discussions on health innovation and investment opportunities in Australia's thriving biotech sector. Thanks to Host State
0
0
1
Dr Kathy Nielsen will also join other industry leaders #AusBiotechInvest2024 for groundbreaking discussions on health innovation and investment opportunities in Australia's thriving biotech sector 📅 Tuesday, 29th October 2024 🧬🔬 #AusBio2024 @VicGovAu
0
0
1
Visit us at the @VicGovAu booth #4. Dr Kathy Nielsen, Dr Francis Kirby, Dr Frederico Calhabeu and Dr Tifelle Reisinger will be in attendance. Kathy will be participating in a panel discussing investing in university spin-outs, 📅 Oct 31, ⏰2:20 PM.🧬🔬 #AusBio2024
1
0
1
Excited to announce BioCurate will be at AusBiotech 2024 #AusBio2024 in Melbourne, 📅 Oct 30-Nov 1! Join us at the Melbourne Convention & Exhibition Centre for cutting-edge biotech discussions, networking, and exploring innovations in life sciences. Let's shape the future of
1
0
1
Excited to be part of the team led by @helenaqcx developing a novel treatment for pulmonary arterial hypertension (PAH) here at @MIPS_Australia. Even more excited to be collaborating with and supported by @BioCurate in this goal. @MIPS_DDB @MonashVHI @OzCvA
Monash University researchers are developing a novel treatment for pulmonary arterial hypertension (PAH), with crucial support from @BioCurate's Proof of Concept Fund. The team aims to create a disease-modifying therapy for this progressive, incurable condition affecting mainly
0
6
21
This collaboration showcases the power of academia-industry partnerships in advancing life-changing therapies. We're excited to see how this project develops and its potential impact on #PAH patients' lives. #MedicalResearch #DrugDiscovery #Innovation #BioCurate
0
1
3
The multidisciplinary team includes Prof @rebeccahritchie , Prof Paul Stupple, Dr @laurentmay, Dr Kieran Stockton, Dr Katie Leach and Julian Vultaggio. Collaborations with @MonashHealth and @AlfredHealth clinicians ensure alignment with patient needs. "We all have the same
1
1
4
BioCurate's support goes beyond funding. "We were very impressed with their thinking about both the scientific and commercial aspects of the project," project lead, Dr @helenaqcx notes. These discussions have helped the team consider unmet needs and develop commercialization
1
1
3
PAH, a progressive and incurable disease, causes pulmonary vessel remodelling and eventual heart failure. The team aims to develop a disease-modifying therapy targeting a G-protein coupled receptor involved in lung vessel inflammation and remodelling.
1
0
3